UA49880C2 - Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі - Google Patents

Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі

Info

Publication number
UA49880C2
UA49880C2 UA98095006A UA98095006A UA49880C2 UA 49880 C2 UA49880 C2 UA 49880C2 UA 98095006 A UA98095006 A UA 98095006A UA 98095006 A UA98095006 A UA 98095006A UA 49880 C2 UA49880 C2 UA 49880C2
Authority
UA
Ukraine
Prior art keywords
receptors
dihydrate
erposartane
pharmaceutical composition
solid dose
Prior art date
Application number
UA98095006A
Other languages
English (en)
Russian (ru)
Inventor
Нагесвара Р. Палепу
Гопаді М. ВЕНКАТЕШ
Сарма ДУДДУ
Original Assignee
Смітклайн Бічам Корпорейшн
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA49880(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смітклайн Бічам Корпорейшн, Смитклайн Бичам Корпорейшн filed Critical Смітклайн Бічам Корпорейшн
Publication of UA49880C2 publication Critical patent/UA49880C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Цей винахід стосується дигідрату монометансульфонату (Е)--[2-н-бутил-1-[(4-карбоксифеніл)метил]-1Н-імідазол-5-іл] метилен-2-тіофенпропіонової кислоти, способу його отримання, композицій, що містять цю сполуку, і способів застосування сполуки для блокування рецепторів ангіотензину II і лікування артеріальної гіпертензії, застійної серцевої недостатності і ниркової недостатності.
UA98095006A 1996-03-29 1997-03-26 Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі UA49880C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29
PCT/US1997/004877 WO1997036874A1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Publications (1)

Publication Number Publication Date
UA49880C2 true UA49880C2 (uk) 2002-10-15

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98095006A UA49880C2 (uk) 1996-03-29 1997-03-26 Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі

Country Status (35)

Country Link
EP (1) EP0889880B1 (uk)
JP (1) JP4316013B2 (uk)
CN (2) CN1214682A (uk)
AP (1) AP901A (uk)
AR (1) AR006439A1 (uk)
AT (1) ATE239723T1 (uk)
AU (1) AU726694B2 (uk)
BG (1) BG64095B1 (uk)
BR (1) BR9708336A (uk)
CA (1) CA2250395C (uk)
CZ (1) CZ293345B6 (uk)
DE (1) DE69721749T2 (uk)
DK (1) DK0889880T3 (uk)
DZ (1) DZ2199A1 (uk)
EA (1) EA001958B1 (uk)
EG (1) EG23889A (uk)
ES (1) ES2198564T3 (uk)
HU (1) HU228263B1 (uk)
ID (1) ID16507A (uk)
IL (1) IL126319A0 (uk)
MA (1) MA24437A1 (uk)
MY (1) MY117682A (uk)
NO (2) NO311760B1 (uk)
NZ (1) NZ332008A (uk)
OA (1) OA11176A (uk)
PL (1) PL188816B1 (uk)
PT (1) PT889880E (uk)
RO (1) RO118870B1 (uk)
SK (1) SK282346B6 (uk)
TR (1) TR199801954T2 (uk)
TW (1) TW434239B (uk)
UA (1) UA49880C2 (uk)
UY (1) UY24504A1 (uk)
WO (1) WO1997036874A1 (uk)
ZA (1) ZA972686B (uk)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4475685B2 (ja) * 1997-06-27 2010-06-09 スミスクライン・ビーチャム・コーポレイション エプロサルタン・一水和物
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
HUP0004407A3 (en) * 1997-11-17 2002-03-28 Smithkline Beecham Corp Immediate and modified release oral dosage formulations containing eprosartan and processes for their manufacture
WO1999044590A1 (en) 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
ZA991922B (en) 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
TR200100172T2 (tr) * 1998-07-20 2001-05-21 Smithkline Beecham Corporation Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
CA2371554C (en) * 1999-04-28 2009-06-09 Shizue Nakagawa Pharmaceutical composition comprising an angiotensin ii antagonist for preventing, treating or development-inhibiting simple retinopathy and preproliferative retinopathy
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
US20040023840A1 (en) * 2000-04-12 2004-02-05 Marc De Gasparo Combination of organic compounds
BR0214383A (pt) * 2001-11-23 2004-11-03 Solvay Pharm Gmbh Tratamento de hipertonia durante a fase aguda do ataque de apoplexia
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AU2003240670A1 (en) * 2002-05-17 2003-12-02 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
JP3874419B2 (ja) 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
WO2009013760A2 (en) 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
JP3214856B2 (ja) * 1990-12-14 2001-10-02 スミスクライン・ビーチャム・コーポレイション イミダゾリル−アルケン酸

Also Published As

Publication number Publication date
MY117682A (en) 2004-07-31
NO311760B1 (no) 2002-01-21
AR006439A1 (es) 1999-08-25
EA199800873A1 (ru) 1999-02-25
RO118870B1 (ro) 2003-12-30
BR9708336A (pt) 1999-08-03
AP901A (en) 2000-11-23
EG23889A (en) 2007-12-12
HUP9902769A3 (en) 2000-04-28
ATE239723T1 (de) 2003-05-15
CZ310198A3 (cs) 1999-03-17
NO984503L (no) 1998-09-28
CA2250395C (en) 2005-09-06
PL188816B1 (pl) 2005-04-29
DZ2199A1 (fr) 2002-12-03
ZA972686B (en) 1997-09-29
AU726694B2 (en) 2000-11-16
WO1997036874A1 (en) 1997-10-09
BG64095B1 (bg) 2003-12-31
CN1214682A (zh) 1999-04-21
DK0889880T3 (da) 2003-09-01
UY24504A1 (es) 1997-09-19
TR199801954T2 (xx) 1998-12-21
MA24437A1 (fr) 1998-10-01
AP9700956A0 (en) 1997-04-30
OA11176A (en) 2003-05-13
BG102822A (en) 1999-11-30
AU2547097A (en) 1997-10-22
EP0889880A1 (en) 1999-01-13
CZ293345B6 (cs) 2004-04-14
IL126319A0 (en) 1999-05-09
HUP9902769A2 (hu) 2000-03-28
PL329046A1 (en) 1999-03-01
NO984503D0 (no) 1998-09-28
CN1332167A (zh) 2002-01-23
EP0889880B1 (en) 2003-05-07
DE69721749T2 (de) 2004-03-25
JP2000508632A (ja) 2000-07-11
PT889880E (pt) 2003-09-30
SK282346B6 (sk) 2002-01-07
CA2250395A1 (en) 1997-10-09
TW434239B (en) 2001-05-16
JP4316013B2 (ja) 2009-08-19
EP0889880A4 (en) 1999-06-23
NZ332008A (en) 1999-05-28
HU228263B1 (en) 2013-02-28
EA001958B1 (ru) 2001-10-22
NO2002005I1 (no) 2002-09-02
HK1016594A1 (en) 1999-11-05
SK132298A3 (en) 1999-03-12
ES2198564T3 (es) 2004-02-01
ID16507A (id) 1997-10-02
DE69721749D1 (de) 2003-06-12

Similar Documents

Publication Publication Date Title
MY117682A (en) Eprosartan dihydrate and a process for its production and formulation
CA2338256A1 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
PL285591A1 (en) Method for manufacturing new imidazolilalkenecrbxylic acids
MX9705313A (es) Benzazepinas triciclicas antagonistas de la vasopresina.
IE902139L (en) Imidazolyl alkenoic acids
MXPA99000214A (es) Antagonistas de la vasopresina, a base de benzazepinas triciclicas.
MX9705415A (es) Antagonsitas de vasopresina triciclicos de benzazepina.
IL140419A0 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
TNSN03083A1 (en) Mercaptoacetylamide derivatives, a process for their preparation and their use
PT78064A (en) Process for preparing benzazocinone and benzazoninone derivatives
HUT59599A (en) Process for producing pharmaceutical compositions containing angiotenzin-ii-receptor-blocking compounds for treating cardial and vascular hypertrofie and/or hyperplasy
ZA991922B (en) Novel compositions of eprosartan.
CA2310028A1 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
MX9707683A (es) Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
IS5579A (is) S-setnir 11ß-bensaldoxím-estra-4,9-díen-karbónsýru þíólesterar, aðferð til framleiðslu á þeim og lyfjasamsetningar sem innhalda þessi efnasambönd
GR3018685T3 (en) Method for the manufacture of a controlled release solid unit dosage form.
UA35607C2 (uk) Похідні оксазолідинонкарбонової кислоти, спосіб їх одержання, фармацевтична композиція і спосіб її одержання
MY118704A (en) Process for preparation of eprosartan
UA77025C2 (en) Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr), a pharmaceutical composition and a method for preparation of compounds
CA2294515A1 (en) Eprosartan monohydrate
DE69705967D1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
HUP0201624A2 (hu) Eprosartan arginin töltéssemlegesítő komplex, valamint eljárás az előállítására és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL158289A0 (en) Mercaptoacetylamide derivatives, a process for their preparation and their use
DE60029493D1 (de) Neues verfahren zur herstellung von 1-phenyl-2-(2-pyridyl)ethanamin
ECSP972071A (es) Dihidrato de eprosartano y un procedimiento para su produccion y formulacion